UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
OncoTargets and therapy, ISSN 1178-6930, 10/2016, Volume 9, pp. 6727 - 6732
Ring formation | Esophageal cancer-associated lymphatic endothelial cells | VEGF-C | Proliferation | Esophageal squamous carcinoma cells | Oncology | Life Sciences & Biomedicine | Biotechnology & Applied Microbiology | Science & Technology | Genetic aspects | Research | Vascular endothelial growth factor | Analysis | Esophageal cancer | Endothelium | Care and treatment | Squamous cell carcinoma | Development and progression | Gene expression | Health aspects | Diabetic retinopathy | Lymphatic system | Laboratories | Brain cancer | Metastasis | Kinases | Design | Angiogenesis | Plasmids | Fibroblasts | Diabetes | Prostate | the alive cells quantity in blank control group were the largest | Endostatin group was for the esophageal cancer cells conditional medium of optimum concentration endostatin processed | SG1 plus endostatin group and SG2 plus endostatin group. There was no statistical significance between the comparison of SG1 group and SG2 group | SG1 group | SG1 plus endostatin group and SG2 plus endostatin group (P >0.05). The comparison between rest groups had statistical significance (P | negative plus endostatin group | the three dimensional culture results of negative control group was the highest | of which were the negative plus endostatin group | SG2 group was for the conditional medium of SG2 plasmid transfected esophageal cancer cells | then followed by blank control group | endostatin group | Negative control group was for the conditional medium of empty plasmid transfected esophageal cancer cells | Objective To investigate the effects of VEGF-C inRNA eukaryotic expression vector and expression of endostatin on esophageal squamous carcinoma-related ring formation in vitro and proliferation of lymphatic endothelial cells. Methods KYSE150 cells were subjected to analysis of cell transfection and endostatin operation. The conditional medium was prepared as well. Blank control group was for the conditional medium of esophageal cancer cells without transfection | negative plus endostatin group did not have statistical significance (P>0.05) | SG1 group and negative plus endostatin group | SG1 plus endostatin group and SG2 plus endostatin group. The esophageal cancer related microlymphatic endothelial cells were three-dimensional cultured and was calculated for the various cells formed tube-like structures. CCK-8 assay was employed to detect the cell proliferation condition. Result Generally comparison | SG2 plus endostatin group. The comparsion between SG1 plus endostatin group and SG2 endostatin group did not have statistical significance (P>0.05) | SG2 group and endostation group | SG2 group and negative plus endostatin group | There were also additional three groups | SG2 group | SG1 group was for the conditional medium of SG1 plasmid transfected with esophageal cancer cells | SG1 group and endostation group | the comparison between rest groups had statistical significance (P | then followed by negative control group | the comparsion between every two of SG1 group | SG1 plus endostatin group
Journal Article
Tumor biology, ISSN 1010-4283, 7/2017, Volume 39, Issue 7, pp. 1 - 9
Angiogenesis | Vascular normalization | Recombinant human endostatin | Anterior gradient 2 | Gold nanoparticles | Life Sciences & Biomedicine | Oncology | Science & Technology | Gold - administration & dosage | Colorectal Neoplasms - genetics | Humans | Endostatins - chemistry | Neovascularization, Pathologic - pathology | Angiogenesis Inhibitors - administration & dosage | Neoplasm Metastasis | Heterografts | Colorectal Neoplasms - drug therapy | Gene Expression Regulation, Neoplastic - drug effects | Gold - chemistry | Human Umbilical Vein Endothelial Cells - drug effects | Neoplasm Proteins - biosynthesis | Metal Nanoparticles - chemistry | Recombinant Proteins - chemistry | Recombinant Proteins - genetics | Recombinant Proteins - administration & dosage | Endostatins - genetics | Proteins - genetics | Cell Movement - drug effects | Animals | Metal Nanoparticles - administration & dosage | Neovascularization, Pathologic - drug therapy | Endostatins - administration & dosage | Cell Line, Tumor | Neovascularization, Pathologic - genetics | Mice | Colorectal Neoplasms - pathology | Angiogenesis Inhibitors - chemistry | Phosphorylation | Authorship | Colorectal carcinoma | Colorectal cancer | Endostatin | Metastasis | Cancer therapies | Metastases | Nanoparticles | Xenografts | Vascular endothelial growth factor receptor 2 | Vascular endothelial growth factor | Gold | Extracellular signal-regulated kinase | FDA approval | Cadherin | Endothelial cells | Gelatinase A | Studies | Chemotherapy | Morphology | Hypoxia | Laboratory animals | Umbilical vein | Cell migration | Tumors | Index Medicus
Journal Article
Biological & pharmaceutical bulletin, ISSN 0918-6158, 2011, Volume 34, Issue 4, pp. 545 - 550
low molecular weight heparin-endostatin | zebrafish | endostatin | polyethylene glycol-endostatin | choroidal neovascularization | Zebrafish | Polyethylene glycol-endostatin | Choroidal neovascularization | Low molecular weight heparin-endostatin | Endostatin | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Heparin, Low-Molecular-Weight - pharmacology | Endostatins - pharmacology | Serpins - metabolism | Endothelial Cells - metabolism | Mice, Inbred C57BL | Angiogenesis Inhibitors - pharmacology | Male | Nerve Growth Factors - metabolism | Vascular Endothelial Growth Factor A - metabolism | Heparin, Low-Molecular-Weight - therapeutic use | Polyethylene Glycols - therapeutic use | Animals | Choroidal Neovascularization - metabolism | Choroidal Neovascularization - drug therapy | Eye Proteins - metabolism | Angiogenesis Inhibitors - therapeutic use | Models, Animal | Cell Proliferation - drug effects | Mice | Endostatins - therapeutic use | Endothelial Cells - drug effects | Polyethylene Glycols - pharmacology | Index Medicus
Journal Article
Kidney international, ISSN 0085-2538, 06/2016, Volume 89, Issue 6, pp. 1281 - 1292
aging kidney | collagen XVIII | fibrosis | tissue transglutaminase | endostatin | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Up-Regulation | GTP-Binding Proteins - pharmacology | Endostatins - pharmacology | Endothelial Cells | Kidney - pathology | Transglutaminases - pharmacology | Cellular Senescence - drug effects | Transglutaminases - genetics | Male | GTP-Binding Proteins - genetics | Folic Acid - toxicity | Kidney - metabolism | Extracellular Matrix Proteins | Kidney Diseases - chemically induced | Collagen Type XVIII - genetics | Collagen Type XVIII - metabolism | Kidney - drug effects | Endostatins - metabolism | Kidney Diseases - pathology | Mice, Inbred C57BL | Cells, Cultured | Mice, Knockout | Endostatins - genetics | Animals | Collagen Type XVIII - pharmacology | Transglutaminases - metabolism | Fibrosis | Mice | Aging - metabolism | GTP-Binding Proteins - metabolism | Index Medicus | collagen 18
Journal Article
Cancer medicine (Malden, MA), ISSN 2045-7634, 04/2019, Volume 8, Issue 4, pp. 1434 - 1441
real‐world study | different administration | chemotherapy | recombinant human‐endostatin | non‐small cell lung cancer | non-small cell lung cancer | real-world study | recombinant human-endostatin | Life Sciences & Biomedicine | Oncology | Science & Technology | Recombinant Proteins - therapeutic use | Lung Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Platinum - therapeutic use | Drug Administration Schedule | Humans | Male | Treatment Outcome | Platinum - administration & dosage | Recombinant Proteins - administration & dosage | Propensity Score | Endostatins - administration & dosage | Survival Analysis | Female | Carcinoma, Non-Small-Cell Lung - drug therapy | Endostatins - therapeutic use | Medical research | Chemotherapy | Gene mutations | Analysis | Genes | Genetic research | Medicine, Experimental | Lung cancer, Small cell | Genetic aspects | Lung cancer, Non-small cell | Cancer | Cell survival | Lung cancer | Endostatin | Non-small cell lung carcinoma | Metastasis | FDA approval | Patients | Cancer therapies | Disease control | Studies | Pathology | Vomiting | Platinum | Consent | Point mutation | Mutation | Index Medicus
Journal Article
American journal of respiratory and critical care medicine, ISSN 1073-449X, 01/2015, Volume 191, Issue 2, pp. 208 - 218
Collagen 18a1 | Genetics | Pulmonary arterial hypertension | Survival | Endostatin | Respiratory System | Life Sciences & Biomedicine | Critical Care Medicine | General & Internal Medicine | Science & Technology | Severity of Illness Index | Hypertension, Pulmonary - mortality | Predictive Value of Tests | Hypertension, Pulmonary - classification | Prognosis | Follow-Up Studies | Humans | Middle Aged | Kaplan-Meier Estimate | Proportional Hazards Models | Hypertension, Pulmonary - genetics | Male | Collagen Type XVIII - blood | Biomarkers - blood | Hypertension, Pulmonary - blood | Endostatins - genetics | Exercise Test | Collagen Type XVIII - genetics | Endostatins - blood | Female | ROC Curve | Ventricular Dysfunction, Right - physiopathology | Polymorphism, Single Nucleotide | Index Medicus | Abridged Index Medicus | collagen 18a1 | genetics | endostatin | Original | pulmonary arterial hypertension | survival
Journal Article
Biomaterials, ISSN 0142-9612, 2013, Volume 34, Issue 26, pp. 6261 - 6271
Advanced Basic Science | Dentistry | Macromolecule transduction domain | Intracellular delivery | Protein therapy | Endostatin | Engineering | Materials Science | Technology | Engineering, Biomedical | Materials Science, Biomaterials | Science & Technology | Human Umbilical Vein Endothelial Cells | NIH 3T3 Cells | Humans | Recombinant Fusion Proteins - therapeutic use | Molecular Sequence Data | Antineoplastic Agents - therapeutic use | Endostatins - chemistry | Antineoplastic Agents - metabolism | Angiogenesis Inhibitors - therapeutic use | Antineoplastic Agents - pharmacokinetics | Endostatins - therapeutic use | Protein Structure, Tertiary | Amino Acid Sequence | Angiogenesis Inhibitors - genetics | Neoplasms - blood supply | Angiogenesis Inhibitors - pharmacokinetics | Recombinant Fusion Proteins - chemistry | Antineoplastic Agents - chemistry | Neoplasms - drug therapy | Endostatins - genetics | Animals | Recombinant Fusion Proteins - pharmacokinetics | Recombinant Fusion Proteins - genetics | Mice | Mice, Inbred BALB C | Neoplasms - pathology | Endostatins - pharmacokinetics | Angiogenesis Inhibitors - chemistry | Medical colleges | Angiogenesis inhibitors | Vascular endothelial growth factor | Collagen | Tumors | Index Medicus
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 08/2006, Volume 24, Issue 22, pp. 3555 - 3561
Biological and medical sciences | Medical sciences | Tumors | Recombinant Proteins - therapeutic use | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Angiogenesis Inhibitors - blood | Angiogenesis Inhibitors - administration & dosage | Self Administration | Antineoplastic Agents - adverse effects | Injections, Subcutaneous | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Female | Endostatins - adverse effects | Angiogenesis Inhibitors - adverse effects | Endostatins - therapeutic use | Carcinoma, Neuroendocrine - blood | Carcinoma, Neuroendocrine - drug therapy | Treatment Outcome | Disease-Free Survival | Carcinoma, Neuroendocrine - pathology | Endostatins - administration & dosage | Survival Analysis | Antineoplastic Agents - blood | Endostatins - blood | Aged | Index Medicus
Journal Article
Carbohydrate polymers, ISSN 0144-8617, 03/2019, Volume 207, pp. 79 - 90
Stability | Anti-angiogenesis | ES2 | Zebra fish | Glycol-split heparin | Physical Sciences | Chemistry | Chemistry, Organic | Polymer Science | Chemistry, Applied | Science & Technology | Endostatins - toxicity | Endostatins - pharmacology | Humans | Half-Life | Female | Glycopeptides - pharmacokinetics | Angiogenesis Inhibitors - chemical synthesis | Cell Line | Oligopeptides - chemical synthesis | Glycopeptides - toxicity | Endostatins - chemical synthesis | Drug Stability | Oligopeptides - pharmacokinetics | Angiogenesis Inhibitors - pharmacology | Zebrafish | Angiogenesis Inhibitors - pharmacokinetics | Oligopeptides - toxicity | Cell Movement - drug effects | Glycopeptides - chemical synthesis | Animals | Angiogenesis Inhibitors - toxicity | Chickens | Mice, Inbred BALB C | Glycopeptides - pharmacology | Oligopeptides - pharmacology | Endostatins - pharmacokinetics | Heparin - chemistry | Index Medicus
Journal Article
Frontiers in pharmacology, ISSN 1663-9812, 2014, Volume 5, pp. 123 - 123
Journal Article